Gene: PCSK9
Official Full Name: proprotein convertase subtilisin/kexin type 9provided by HGNC
Gene Summary: This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO01714 | PCSK9 Knockout cell line (HeLa) | Human | PCSK9 | 1:3~1:6 | Negative | Online Inquiry |
KO01715 | PCSK9 Knockout cell line (HCT 116) | Human | PCSK9 | 1:2~1:4 | Negative | Online Inquiry |
KO01716 | PCSK9 Knockout cell line (A549) | Human | PCSK9 | 1:3~1:4 | Negative | Online Inquiry |
PCSK9 Gene Knockout Cell Lines are specially engineered cell lines that have undergone targeted genomic modifications to effectively disable the PCSK9 gene, which encodes the proprotein convertase subtilisin/kexin type 9 protein. This protein is pivotal in regulating lipid metabolism, particularly by modulating the degradation of LDL receptors, thereby influencing cholesterol levels in plasma. The knockout of the PCSK9 gene results in enhanced expressions of LDL receptors on cell surfaces, facilitating improved clearance of LDL cholesterol from the bloodstream and holding implications for therapeutic strategies against hypercholesterolemia and cardiovascular diseases.
These cell lines function through the mechanisms of gene editing techniques, such as CRISPR/Cas9, resulting in a precise disruption of PCSK9 expression. Researchers can utilize these knockout models to study the fundamental processes of cholesterol metabolism, explore the physiological roles of PCSK9, and validate the effectiveness of novel pharmacological agents targeting this pathway. The implications of such research extend to the development of PCSK9 inhibitors, a class of drugs that have emerged as revolutionary treatments for high cholesterol levels.
What sets our PCSK9 Gene Knockout Cell Lines apart from alternative models is their high purity, consistency, and the robust data derived from their use in various assays, which can accelerate the pace of research breakthroughs. Additionally, these cell lines are accompanied by comprehensive technical documentation and support, making them user-friendly for both seasoned and novice researchers.
For clinicians and researchers focused on lipidology and cardiovascular health, our knockout cell lines offer an unprecedented opportunity to generate insights that could translate to improved patient outcomes. This product not only streamlines the research process but also enhances the accuracy of experimental results. Our commitment to excellence in the development of biological products is backed by years of expertise in cellular biology and genetic research, ensuring that our offerings meet the highest scientific standards.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.